No Data
No Data
ATyr Pharma to Present at Upcoming Investor Conferences
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its pro
HC Wainwright & Co. : The ATyr Pharma (LIFE.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $35.00.
HC Wainwright & Co. : The ATyr Pharma (LIFE.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $35.00.
RBC Capital Sticks to Their Buy Rating for ATyr Pharma (LIFE)
Strong Buy Rating for ATyr Pharma as Efzofitimod Shows Promise and Financial Stability
ATyr Pharma Q1 EPS $(0.23) Beats $(0.24) Estimate, Sales $235.00K Beat $20.00K Estimate
aTyr Pharma (NASDAQ:LIFE) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.24) by 4.17 percent. This is a 20.69 percent increase over losses of $(0.29) p
Earnings Flash (LIFE) ATYR PHARMA Reports Q1 Revenue $235,000
04:00 PM EDT, 05/02/2024 (MT Newswires) -- Earnings Flash (LIFE) ATYR PHARMA Reports Q1 Revenue $235,000